Early application of Shakubatracvalsartan in elderly patients with acute myocardial infarction and heart failure after interventional therapy
10.3760/cma.j.issn.0254-9026.2023.09.005
- VernacularTitle:老年急性心肌梗死合并心力衰竭患者介入治疗后早期应用沙库巴曲缬沙坦的研究
- Author:
Man LI
1
;
Yong WANG
;
Zhijian WANG
;
Zhifeng BAI
Author Information
1. 商丘市第一人民医院心内二科，商丘 476100
- Keywords:
Acute myocardial infarction;
Acute heart failure;
Augioplasty, Transluminal, percutaneous coronary intervention;
Shakubatracvalsartan
- From:
Chinese Journal of Geriatrics
2023;42(9):1047-1051
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To examine the clinical effect of early administration of Shakubatracvalsartan following early percutaneous coronary intervention(PCI)in patients diagnosed with acute myocardial infarction and acute heart failure.Methods:This study prospectively included 65 patients with acute myocardial infarction and acute heart failure who were admitted to the First People's Hospital of Shangqiu from June 2018 to October 2022.The patients were randomly divided into two groups: the control group(35 cases)and the observation group(30 cases).Both groups received early PCI treatment.After the operation, the control group received oral administration of Benazepril hydrochloride, while the observation group received oral administration of Shakubatracvalsartan for a duration of 8 weeks.The study compared the total treatment efficiency and cardiac function parameters, such as left ventricular ejection fraction(LVEF), left ventricular end-diastolic diameter(LVEDD), and clear brain natriuretic peptide precursor(NT-proBNP)as well as myocardial injury markers(creatine kinase isoenzyme MB(CK-MB)and myoglobin(Myo))before and at 8 weeks of treatment between the two groups.Additionally, any adverse effects that occurred during the treatment period were also compared.Results:The total effective rate was 93.33%(28 cases)in the observation group and 71.43%(25 cases)in the control group.The observation group had a higher rate compared to the control group, and this difference was statistically significant( χ2=5.149, P<0.05).Both groups showed an increase in left ventricular ejection fraction, a decrease in left ventricular end-diastolic diameter, and a decrease in N-terminal pro-brain natriuretic peptide.In the observation group, the left ventricular ejection fraction was(48.52±3.28)%, which was higher than the control group's(43.86±2.52)%, and the left ventricular end-diastolic diameter was(46.70±2.88)mm and the N-terminal pro-brain natriuretic peptide was(680.44±87.04)pg/L, which were lower than the control group's(50.46±3.47)mm and(1 715.94±115.41)pg/L, respectively.These differences were statistically significant( t=13.434, 5.287, 5.330, P<0.05 for all).The levels of creatine kinase-MB and myoglobin in both groups were significantly lower after treatment.Specifically, the observation group had levels of(31.42±5.76)U/L and(34.42±5.36)mg/L, which were lower than the levels in the control group of(38.44±4.94)U/L and(43.15±7.46)mg/L.These differences were statistically significant( t=5.287, 5.330, P<0.05 for all).The readmission rate was 10.00%(3 cases)in the observation group and 14.29%(5 cases)in the control group.The readmission rate of the observation group was lower than that of the control group, and the difference was not statistically significant( χ2=0.021, P>0.05). Conclusions:The early administration of Shakubatracvalsartan following early PCI has been shown to effectively enhance cardiac function in patients with acute myocardial infarction and acute heart failure.It also facilitates the repair of myocardial cells and improves the therapeutic outcomes after surgery.
